Happy Mother's Day! It's a bit different this year, of course, but I hope you get a chance to honor, if possible, the person who brought you into this world, and if you have one, the partner who's helping you get through it. I wanted to write this week's col…

Let us take a look at five drug/biotech companies due to release their first-quarter financial results on May 6.

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

Google Meet is a video conferencing service from Google. It’s a great solution for both individuals and businesses to meet on audio and video calls. It was born from Google Hangouts, but boasts some unique features. In this article, we take a look at Google M…

For a show that’s ostensibly a comedy, Greg Daniels’ new Amazon series Upload ended its first season on a decidedly dark note, full of deaths, separations, and the horrific specter of a limited data plan. (And when you’re using “data” to keep your consciousne…

VFX supervisor Marshall Krasser on the challenge of keeping it real—but not too real.

Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.

Amazon’s new sci-fi comedy hasn’t finished uploading. The streamer has renewed “Upload,” which hails from “The Office” and “Parks and Recreation” creator Greg Daniels, for a second season exactly a week after its first season dropped. “Upload” takes place in …

Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season

This is a big step in the right direction. What you need to know All of Google's chat/communication apps are now being led by one person. Javier Soltero is now in charge of G Suite, Messages, Duo, and Google's phone app. There are currently no plans to m…

Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.

It’s no question that during the global pandemic, Google was undoubtedly unprepared for the spike in video conferencing, leaving Zoom to claim the mantle of “that one program everyone uses to video chat now.” But starting in early May, anyone with a Google Ac…

It’s difficult to talk about Greg Daniels’ new Amazon series Upload without invoking comparisons to the work of his old pal Michael Schur—specifically, The Good Place. Both shows come from alumni of some of the most popular sitcoms in recent TV history. Both …

From Ryan Murphy's juicy look at Tinseltown tawdriness to a controversial doc about sexual harassment in the music industry — what to see this month

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14) * Allogene Therapeutics Inc (NASDAQ: ALLO)(reacted to ASCO abstract) * Altimmune Inc (NASDAQ: ALT)(announced first-quarter results and update to its COVID-19 vaccine program) * BioXcel Therapeutics Inc (NASDAQ: BTAI)( announced full enrollment of Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorder and said it expects results from the two studies in July) * Co-Diagnostics Inc (NASDAQ: CODX) * Myokardia Inc (NASDAQ: MYOK) * Repligen Corporation (NASDAQ: RGEN) * Translate Bio Inc (NASDAQ: TBIO) * VBI Vaccines Inc (NASDAQ: VBIV)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 14) * Genfit SA (NASDAQ: GNFT) * Lyra Therapeutics Inc (NASDAQ: LYRA) (IPOed May 1) * RA Medical Systems Inc (NYSE: RMED)(reacted to first-quarter results) * Recro Pharma Inc (NASDAQ: REPH) * Sensus Healthcare Inc (NASDAQ: SRTS) * Sonnet Biotherapeutics Holdings Inc (NASDAQ: SONNStocks In Focus NantKwest To Start Mid-Stage Study Of Pancreatic Cancer Drug Combo In June Nantkwest Inc (NASDAQ:NK) announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of a combination immunotherapy: NantKwest's PD-L1 t-haNK, ImmunityBio's N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.The company noted that out of the four patients treated with PD-L1 t-haNK and N-803 under single patient INDs, two were on treatment for the evaluable period. Of these two patients, one reported ongoing, durable, complete response six months after treatment, and one observed response of stable disease. It expects to begin the Phase 2 study in June."Our results from expanded access use of PD-L1 t-haNK in combination with N-803 offer proof-of-concept that, together with these agents, the immune system may play a role to activate robust and durable responses in metastatic cancer patients who have failed all standard-of-care therapies, said Patrick Soon-Shiong, CEO of NantKwest and ImmunityBio.NantKwest stock fell 8.54% to $4.71 in after-hours trading.Phio Presents Encouraging Data For Gene Silencing Platform Phio Pharmaceuticals Corp (NASDAQ: PHIO) announced data analyzing the applicability of the INTASYL platform as a gene silencing technology that offers an alternative or complementary approach to gene editing technologies, such as CRISPR/Cas9, in the treatment of solid tumors.The data presented as a poster at the American Society of Gene and Cell Therapy 23rd Virtual Annual Meeting showed that INTASYL compared favorably to other technologies for improving cells used in adoptive cell therapy for the treatment of solid tumors, especially in cases where permanent gene modification is not required or is undesirable.The stock rose 5.14% to $2.25 in after-hours trading.Earnings Sellas Life Sciences Group Inc (NASDAQ: SLS) reported a first-quarter net loss of 66 cents per share compared to a loss of $11.12 per share last year. Analysts estimated a wider loss of 74 cents per share. Cash and cash equivalents totaled about $6.7 million at the end of March 31, 2020, compared to $2.6 million as of March 31, 2019The stock rallied 13.24% to $3.25 in after-hours trading.Applied DNA Sciences Inc's (NASDAQ: APDN) fiscal year second-quarter revenues fell 29% year-over-year to $552,000. The net loss narrowed from $1.12 per share to 79 cents per share. Analysts, on average, estimated a loss of 77 cents per share on revenues of $950,000.View more earnings on IBBIn after-hours trading, the stock was down 11.77% to $13.42.TFF Pharmaceuticals Inc (NASDAQ: TFFP) reported a first-quarter loss of 20 cents per share compared to a loss of 55 cents per share a year ago. Analysts estimated a loss of 24 cents per share. The stock jumped 17.02% to $5.50 in after-hours trading.Co-Diagnostics reported a strong increase in its first-quarter revenues to $1.55 million from $3,400 a year ago. The loss per share narrowed from 9 cents to 5 cents, in line with estimate.Offering a mid-quarter update for the second quarter, the company said it has manufactured more than 6 million COVID-19 tests to date and has ordered for components for more than 20 million additional tests. The company also said its test kit showed 100% specificity and 100% sensitivity in several independent evaluations.The stock retreated 15.95% to $18.60 in after-hours trading.Offerings TG Therapeutics Inc common stock (NASDAQ: TGTX) priced its upsized underwritten public offering of 8.5 million shares at $18 per share for raising gross proceeds of $153 million. All the shares are being offered by the company. The company expects the offering to close May 19.The stock slipped 2.26% to $19.48 in after-hours trading.Boston Scientific Corporation (NYSE: BSX) priced its public offering of $1.7 billion aggregate principal amount of its senior notes.The public offering consists of $500 million in aggregate principal amount of 1.90% notes due 2025 and $1.2 billion in aggregate principal amount of 2.65% notes due 2030. The company intends to use the net proceeds to repay its debt.Oyster Point Pharma Inc (NASDAQ: OYST) priced its underwritten public offering of 3.75 million shares at $28 per share. All of the shares are being offered by the company. The offering, which is expected to close May 19, is likely to generate gross proceeds of $105 million for the company.The stock was slipping 6.31% to $30.01 in premarket trading Friday.On The Radar PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS) awaits FDA nod for an expanded indication for its cancer therapy Rubraca. The sNDA seeks approval of Rubraca as monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.Clinical Readouts Pfizer Inc. (NYSE: PFE) will present at the ASGCT meeting, Phase 1b data for PF-06939926 in Duchenne muscular dystrophy at 10 am ET.Earnings Digirad Corporation (NASDAQ: DRAD) (before the market open) * Zyla Life Sciences (OTC: ZCOR) (before the market open) * PLx Pharma Inc (NASDAQ: PLXP) (before the market open) * Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP) (before the market open) * Bio-Path Holdings Inc (NASDAQ: BPTH) (before the market open)IPO Late clinical-stage oncology-focused Swiss biotech ADC THERAPEUTICS priced its upsized initial public offering of 12,245,631 shares of its common shares at $19.00 per share, above the estimated price range of $16-18. The company expects the offering to generate gross proceeds of $232.7 million. The shares are to be listed on the NYSE under the ticker symbol "ADCT."See more from Benzinga * The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger * The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Oral Presentation is the First Data Readout from this Dose Escalation Study of ALLO-501, an Allogeneic Anti-CD19 CAR T TherapyALPHA Study Utilizes ALLO-647 Administered as Part.

CLLS earnings call for the period ending March 31, 2020.

The newest series from "The Office" and "Parks & Recreation" co-creator Greg Daniels has a few interesting component parts, but it mostly feels like a thinned-out, 10-episode comedy sketch.

Take Black Mirror's dystopian tech commentary, The Good Place's philosophical exploration of the after-life, and the workplace antics of The Office, mash them together, and you have Amazon’s Upload. It takes place in a world that could easily be 10 years from…

On Wednesday, Allogene (ALLO) revealed positive initial data from its ALLO-501 CD19 allogeneic CAR T, showing both activity and a tolerable safety profile. The news sent shares surging 28% in Wednesday’s after-hours trading.Allogene announced preliminary data from the Phase 1 dose escalation ALPHA trial of ALLO-501 in conjunction with the release of ASCO (American Society of Clinical Oncology) abstracts.As of the January cutoff, 3 non-Hodgkin lymphoma (NHL) patients achieved complete responses and 4 achieved partial responses, for an ORR [overall response rate] of 78% (n=7/9).“Although early, we believe these data suggest that ALLO-501 could go toe-to-toe with autologous CAR-Ts on performance and safety—setting a new bar for allogeneic CAR-Ts in NHL and underscoring the importance of Allogene’s antibody-dependent approach to lymphodepletion” commented Oppenheimer’s Mark Breidenbach following the report.He anticipates updated results from 11 evaluable patients in the May 29 oral presentation at ASCO—including patients treated with high-dose ALLO-647, which may further improve efficacy.As a result of these ‘encouraging early results’, Breidenbach reiterated his buy rating on the stock while ramping up his price target from $44 to $50 (61% upside potential).Meanwhile JP Morgan’s Cory Kasimov wrote: “In our view, this is good initial data but it hard to interpret relative to other CAR T / CD19 approaches given the limited details in the abstract (i.e. what doses, which histologies, and the amount of follow-up for patients still responding).”Ultimately, the JP Morgan analyst looks to the upcoming ASCO presentation (which will also include patients treated at a higher ‘647 dose) to further evaluate.ALLO currently shows a cautiously optimistic Moderate Buy consensus from the Street with 7 recent buy ratings vs 4 hold ratings. The average analyst price target stands at $34 (11% upside potential). (See ALLO stock analysis on TipRanks).Related News: Moderna’s COVID-19 Vaccine Candidate Progressing at ‘Warp Speed,’ Says Top Analyst Twilio Partners With Zocdoc For Telehealth Video Consultations CymaBay (CBAY) Stock Is up 127% in a Day. How Much Higher Can It Go? More recent articles from Smarter Analyst: * Tesla Asks China To Build Model 3 Cars With LFP Batteries - Report * Beleaguered Hertz Sinks 36% In After-Market On Bankruptcy Protection Filing * Amarin Down 10% in Pre-Market On Generic Approval * Alibaba Scores Earnings Beat With Revenue Surging 22% Y/Y

Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology.

Webinar Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company.

The development-stage biopharma reported encouraging, albeit early, data from an important pipeline program.

In Greg Daniels’ new Amazon Prime series Upload, Robbie Amell plays Nathan, a self-centered pretty boy who finds himself unexpectedly “uploaded” after a suspicious self-driving car accident. Andy Allo is Nora, his “angel,” and his guide to his digital afterli…

As of late, it has definitely been a great time to be an investor Allogene Therapeutics

In this sci-fi comedy series, the afterlife is a virtual world nearly as maddening as our own

The development-stage biopharma reported encouraging, albeit early, data from an important pipeline program.

In this time of social distancing and spending a lot more of your day at home, chances are you're watching all kinds of movies and TV shows, including plenty of action and horror titles. It definitely seems like the plethora of streaming services available we…

Is (ALLO) Outperforming Other Medical Stocks This Year?

Allogene Therapeutics, Inc. (ALLO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Company Developed TurboCAR™ Technology Allows Cytokine Activation Signaling to be Engineered Selectively into CAR T CellsPreclinical Studies Provide Evidence That Cytokine.

ALLO earnings call for the period ending March 31, 2020.

Allogene Therapeutics (ALLO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

ALLO earnings call for the period ending March 31, 2020.

Greg Daniels has been working on Upload for a very long time.  In fact, the buzzy sci-fi series, out today on Amazon Prime Video, has been sitting in The Office writer’s notebook since his first major TV job over thirty years ago. “So I'm in New York working …

Allogene (ALLO) reports no revenues for the first quarter of 2020.

Our task was to create concept for autumn promo-campaign to tell about great offer — extended warranty in ALLO. We made the line of visuals in the movie disaster stylization. If the most terrible events happened, aliens attack, hurricane, tsunami, the warrant…

ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host DiseaseAbstract Based on.

Best answer: Google Meet is one of Google's videoconferencing platforms that comes bundled as part of the company's enterprise software package known as G Suite. Google is making Meet free to use from May through September 2020, and it is a solid alternative …